Dr. Muhammad Fawad Rasool

🚀 The American Heart Association's PREVENT Equations are here to revolutionize risk assessment for adults aged 30-79!
Developed and rigorously validated, these equations address the limitations of current methods, providing precise predictions of cardiovascular disease (CVD) risk. By analyzing data from a whopping 6,612,004 adults, these equations accurately forecasted CVD events over a 4.8-year follow-up period. What's more, they're tailored for diverse populations and incorporate readily available clinical data. From traditional risk factors to optional predictors like urine albumin-to-creatinine ratio and hemoglobin A1c, these equations offer comprehensive insights into CVD risk. It's a monumental step forward in preventive care, empowering clinicians and patients alike to take proactive measures for heart health. Get ready to embrace a new era of precision medicine! 💪🫀💡
Read Full Article @ https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067626

Development and Validation of the American Heart Association’s PREVENT Equations BACKGROUND: Multivariable equations are recommended by primary prevention guidelines to assess absolute risk of cardiovascular disease (CVD). However, current equations have several limitations. Ther

🔬💊 Exciting Update from FDA's CDER! Introducing their 13th annual report: "Advancing Health Through Innovation: New Drug Therapy Approvals". Discover how CDER is revolutionizing healthcare by ensuring safe and effective drugs reach patients and consumers.

In 2023, amidst significant public health milestones, including the end of the COVID-19 Public Health Emergency, CDER continued its vital work. Notably, they greenlit the first oral antiviral pill for COVID-19 and are actively supporting further advancements in this field.

Their 2023 New Drug Therapy Approvals Report spotlights CDER's groundbreaking actions, including the approval of 55 novel drugs and expansions of existing drug uses. These approvals target a spectrum of diseases like infectious diseases, neurological conditions, opioid abuse, heart diseases, and more.

Patients with rare diseases found hope in their approvals, with 51% of novel drugs targeting rare conditions like Friedreich’s ataxia, Rett syndrome, and Paroxysmal nocturnal hemoglobinuria. Moreover, they tackled rare cancers such as mantle cell lymphoma and nasopharyngeal carcinoma.

In enhancing their review process, they achieved remarkable efficiencies. They met Prescription Drug User Fee Act goals for 89% of approvals, approved 84% of novel drugs on the first cycle, and prioritized U.S. approvals for 64% of novel drugs.

Their commitment to expedited programs for serious conditions saw 65% of novel drug approvals utilizing these pathways, ensuring swift access to life-changing therapies.

Celebrating innovation and progress in healthcare! 💪🌟
Read Full Report @ https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2023